Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3927283 | 1.00 | KDM4A (0.33) | KDM4AKDM2AACHE | |
| SCHEMBL4584622 | 0.99 | KDM4A (0.34) | KDM4AKDM2AACHE | |
| SCHEMBL4584627 | 0.99 | KDM4A (0.34) | KDM4AKDM2AACHE | |
| Bromide SCHEMBL3927286 | 0.98 | KDM4A (0.33) | KDM4AKDM2AACHE | |
| Bromide SCHEMBL3930970 | 0.88 | MEN1 (0.36) | KDM4AKDM2A | |
| Bromide SCHEMBL3930965 | 0.88 | MEN1 (0.36) | KDM4AKDM2A | |
| SCHEMBL4602896 | 0.87 | MEN1 (0.36) | KDM4AKDM2A | |
| SCHEMBL4602891 | 0.87 | MEN1 (0.36) | KDM4AKDM2A | |
| Bromide SCHEMBL3939318 | 0.84 | NPC1 (0.41) | KDM4AKDM2AACHE | |
| Bromide SCHEMBL3939304 | 0.84 | NPC1 (0.41) | KDM4AKDM2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569079-B2 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | L'OREAL S.A. (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080263785-A1 | Polycationic monochromophoric hydrazone compounds, dye compositions comprising such polycationic compounds and dyeing process using them | KRT18, CKMT1A; CKMT1B, XRCC5 | ACHE 2633/4885KDM4A 716/4885KDM2A 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.